Scholarlink

Objective <p>This study aimed to investigate the clinical manifestations and therapeutic strategies for cirrhosis concurrent with NK/T-cell lymphoma and hemophagocytic lymphohistiocytosis (HLH), to enhance diagnostic and therapeutic insights into this rare disease with triple comorbidity.</p> Methods <p>We retrospectively analyzed the clinical data and diagnostic-therapeutic workflow of a patient admitted to our hospital in August 2024 with cirrhosis, NK/T-cell lymphoma, and HLH.</p> Results <p>The patient was admitted to the Department of Infectious Diseases of our hospital with cirrhosis of unknown origin. Laboratory findings demonstrated trilineage cytopenia, coagulopathy, deranged blood biochemistry, markedly elevated ferritin, and hypercytokinemia. Serological testing confirmed Epstein-Barr virus (EBV) antibody positivity, while molecular assays detected high EBV DNA loads. Bone marrow cytomorphology and cervical lymph node histopathology corroborated NK/T-cell lymphoma with HLH. Whole-body PET/CT revealed multifocal lymph node involvement. Following multidisciplinary evaluation, the patient underwent hematology-directed management combining hepatoprotective therapy, antimicrobials, and chemotherapy (gemcitabine/oxaliplatin/mitoxantrone liposome), stabilizing disease.</p> Conclusion <p>The co-occurrence of cirrhosis, NK/T-cell lymphoma, and HLH represents a rare clinical entity with a grim prognosis. This case highlights the necessity of early recognition and coordinated multidisciplinary interventions to optimize outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A case of cirrhosis concurrent with NK/T-Cell lymphoma and hemophagocytic lymphohistiocytosis: a clinical report and literature review

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月4日

查看全文
  • Delei Li,
  • Xu Xiang

摘要

Objective

This study aimed to investigate the clinical manifestations and therapeutic strategies for cirrhosis concurrent with NK/T-cell lymphoma and hemophagocytic lymphohistiocytosis (HLH), to enhance diagnostic and therapeutic insights into this rare disease with triple comorbidity.

Methods

We retrospectively analyzed the clinical data and diagnostic-therapeutic workflow of a patient admitted to our hospital in August 2024 with cirrhosis, NK/T-cell lymphoma, and HLH.

Results

The patient was admitted to the Department of Infectious Diseases of our hospital with cirrhosis of unknown origin. Laboratory findings demonstrated trilineage cytopenia, coagulopathy, deranged blood biochemistry, markedly elevated ferritin, and hypercytokinemia. Serological testing confirmed Epstein-Barr virus (EBV) antibody positivity, while molecular assays detected high EBV DNA loads. Bone marrow cytomorphology and cervical lymph node histopathology corroborated NK/T-cell lymphoma with HLH. Whole-body PET/CT revealed multifocal lymph node involvement. Following multidisciplinary evaluation, the patient underwent hematology-directed management combining hepatoprotective therapy, antimicrobials, and chemotherapy (gemcitabine/oxaliplatin/mitoxantrone liposome), stabilizing disease.

Conclusion

The co-occurrence of cirrhosis, NK/T-cell lymphoma, and HLH represents a rare clinical entity with a grim prognosis. This case highlights the necessity of early recognition and coordinated multidisciplinary interventions to optimize outcomes.